Article
Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease.
Drug metabolism and disposition: the biological fate of chemicals - 1 May 2018
Tirona Rommel G, Kassam Zahra, Strapp Ruth, Ramu Mala, Zhu Catherine, Liu Melissa, Schwarz Ute I, Kim Richard B, Al-Judaibi Bandar, Beaton Melanie D
Abstract excerpt
There is little known about the impact of nonalcoholic fatty liver disease (NAFLD) on drug metabolism and transport. We examined the pharmacokinetics of oral apixaban (2.5 mg) and rosuvastatin (5 mg) when administered simultaneously in subjects with magnetic resonance imaging-confirmed NAFLD (N = 22) and healthy control subjects (N = 12). The area under the concentration-time curve to the last sampling time...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.